Novavax (NVAX) Misses Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Novavax (NVAX) Misses Q4 EPS by 5c

Novavax Reports Fourth Quarter and Year-End 2014 Financial Results

February 26, 2015 4:18 PM EST

GAITHERSBURG, Md., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced its financial results for the fourth quarter and twelve months ended December 31, 2014.

Corporate Highlights

Fourth Quarter and Subsequent Achievements:

RSV

Initiated a Phase 2 clinical trial of its RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) in 1,600 elderly adults (60 years of age); Received the U.S. Food and Drug Administration's (FDA) Fast... More